Table 1.
Patient characteristics in the prospective and retrospective cohort.
| Characteristics | Retrospective cohort (n = 63) | Prospective cohort (n = 144) | p value |
|---|---|---|---|
| Age (years), median (range) | 46 (18–65) | 44 (16–70) | 0.6 |
| Male, n (%) | 37 (58) | 81 (56) | 0.7 |
| Baseline disease, n (%) | |||
| • AL and other myeloid disorders | 49 | 108 | 0.4 |
| • Lymphoid disorders | 13 | 31 | |
| • Others | 1 | 5 | |
| Disease status at transplant, n (%) | |||
| • CR | 54 (86) | 99 (69) | 0.1 |
| • PR | 2 (3) | 12 (8) | |
| • Refractory/active disease | 7 (11) | 33 (23) | |
| Prior Auto-HCT, n (%) | 7 (11) | 38 (26) | 0.03 |
| Period of transplant, n (%) | |||
| • 2016–2018 | 2 | 115 | |
| • 2013–2015 | 43 | 15 | |
| • 2010–2012 | 10 | 6 | |
| • Before 2010 | 8 | 8 | |
| Conditioning regimen, n (%) | |||
| • RIC | 15 (24) | 60 (42) | 0.04 |
| Type of donor, n (%) | |||
| • HLA-identical sibling donor | 22 (35) | 55 (38) | 0.001 |
| • Unrelated donor | 3 (5) | 34 (24) | |
| • Umbilical cord blood | 30 (48) | 18 (13) | |
| • Haploidentical family donor | 7 (11) | 37 (26) | |
| PB stem cell source, n (% | 33 (53) | 121 (84) | 0.01 |
| HLA fully-matched, n (%) | 25 (40) | 89 (62) | 0.02 |
| ATG as a part of conditioning regimen, n (%) | 29 (46) | 24 (17) | 0.001 |
| GvHD prophylaxis, n (%) | |||
| • Sir-Tac | 1 (2) | 1 (1) | 0.001 |
| • CsA + MTX | 23 (37) | 30 (21) | |
| • Post-Cy | 7 (11) | 89 (62) | |
| • CsA + PDN and Others | 32 (51) | 24 (17) | |
| Length of observation period, months | 40 | 31 | |
| Number CARV episodes | 108 | 297 | |
| Median time from allo-HCT to CARV, days (range) | 252 (−7-6177) | 193 (−7-4894) | 0.03 |
| Median F/U after CARV, days (range) | 613 (6-2147) | 217 (1-799) | |
Abbreviations: AL, acute leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disease; CR, complete remission; PR, partial remission; Auto-HCT, autologous stem cell transplantation; RIC, reduced intensity conditioning; ATG, anti-thymocyte globulin; Sir, sirolimus; Tac, tacrolimus; CsA, cyclosporine A; MTX, methotrexate; Post-Cy, post-transplant cyclophosphamide; PDN, prednisone; SC, stem cell; allo-HCT, allogeneic hematopoietic stem cell transplantation; CARV, community-acquired respiratory virus; F/U, follow-up.